Chrysalis

Executive Summary

Chrysalis is a Boston-based provider of flexible, on-demand GMP cleanroom hosting and support services for the biotech and pharmaceutical industries. Founded in 2016, the company addresses critical manufacturing bottlenecks for biologics and advanced therapies by offering scalable, compliant infrastructure—including ISO 7 cleanrooms, environmental monitoring, GMP warehousing, and cleaning services. Its asset-light model allows innovators to accelerate manufacturing timelines without the high capital expenditure of building and maintaining their own cleanroom facilities, positioning Chrysalis as a key enabler of faster time-to-market for novel therapeutics. The growing demand for biologics and cell/gene therapies, coupled with ongoing capacity constraints in the contract manufacturing space, creates a favorable market backdrop for Chrysalis. The company's focus on compliance and operational flexibility helps clients navigate regulatory hurdles while maintaining supply chain agility. With its early-stage profile, Chrysalis is well-positioned to capture market share as biotech firms increasingly seek outsourcing partners that can reduce risk and shorten development cycles. Continued expansion of its cleanroom capacity and service offerings will be critical to scaling its customer base and establishing long-term contracts with leading innovators.

Upcoming Catalysts (preview)

• Q4 2026New cleanroom facility expansion or second site announcement60% success
• Q3 2026First major client partnership with a biotech or pharma company50% success
• Q2 2026Regulatory milestone: successful FDA inspection or ISO certification renewal70% success